Login to Your Account

New River Signs Potential $500M Deal With Shire For ADHD Drug

By Jennifer Boggs

Tuesday, February 1, 2005
New River Pharmaceuticals Inc. could receive $500 million in a collaboration deal with Shire Pharmaceuticals Group plc for global commercialization of New River's Phase III compound being developed for attention deficit hyperactivity disorder. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription